Materias dentro de su búsqueda.
Mostrando 581 - 585 Resultados de 585 Para Buscar '"Mainz"', tiempo de consulta: 1.06s Limitar resultados
  1. 581
    “…On 21 December 2020, the European Commission granted conditional marketing authorisation for the messenger RNA vaccine ‘Comirnaty’, produced by Pfizer (New York, NY, USA) and BioNTech (Mainz, Germany). This happened only twelve months after the first identification of the virus, whereas the development and approval of vaccines usually take ten years. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    The Promises of Speeding Up: Changes in Requirements for Animal Studies and Alternatives during COVID-19 Vaccine Approval–A Case Study
  2. 582
    por Ulmer, Stefan
    Publicado 2022
    “…Yamazaki </strong>$^{1}$</span></span></span></p> <p>$^{1}$<span><span><span><span>&nbsp;RIKEN, Ulmer Fundamental Symmetries Laboratory, Saitama, Japan; </span></span></span></span>$^{2}$&nbsp;<span><span><span><span>Johannes Gutenberg-Universität, Mainz, Germany; </span></span></span></span>$^{3}$<span><span><span><span>&nbsp;Max-Planck-Institut für Kernphysik, Heidelberg, Germany; $^{4}$&nbsp;PTB, Braunschweig, Germany; $^{5}$&nbsp;CERN, Geneva, Switzerland; $^{6}$&nbsp;The University of Tokyo, Tokyo, Japan; $^{7}$&nbsp;GSI - Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany; $^{8}$&nbsp;ETH, Zuerich, Switzerland;</span></span></span></span></p> <p>&nbsp;</p> <p><span><span>The Standard Model of particle physics is both incredibly successful and glaringly incomplete. …”
    Enlace del recurso
    Studies of Exotic Physics with Antiprotons and Protons
  3. 583
    “…We assessed the immunogenicity and reactogenicity of BNT162b2 (Comirnaty, BioNTech, Mainz, Germany) administered as second dose in participants primed with ChAdOx1-S (Vaxzevria, AstraZeneca, Oxford, UK). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
  4. 584
    “…We aimed to assess the reactogenicity and immunogenicity of heterologous immunisations with ChAdOx1 nCov-19 (AstraZeneca, Cambridge, UK) and BNT162b2 (Pfizer-BioNtech, Mainz, Germany) compared with homologous BNT162b2 and ChAdOx1 nCov-19 immunisation. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study
  5. 585
    “…FUNDING: Deutsche Krebshilfe, Elternverein für Krebs-und leukämiekranke Kinder Gießen, Kinderkrebsstiftung Mainz, Tour der Hoffnung, Menschen für Kinder, Programme Hospitalier de Recherche Clinique, and Cancer Research UK.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial
Herramientas de búsqueda: RSS